ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AQST Aquestive Therapeutics Inc

2.75
-0.06 (-2.14%)
Last Updated: 12:58:19
Delayed by 15 minutes

Period:

Draw Mode:

Volume 435,300
Bid Price 2.75
Ask Price 2.76
News (1)
Day High 2.885

Low
1.2514

52 Week Range

High
6.23

Day Low 2.72
Share Name Share Symbol Market Stock Type
Aquestive Therapeutics Inc AQST NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.06 -2.14% 2.75 12:58:19
Open Price Low Price High Price Close Price Previous Close
2.8101 2.72 2.885 2.81
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
3,580 435,300 US$ 2.78 US$ 1,209,094 - 1.2514 - 6.23
Last Trade Type Quantity Price Currency
12:58:51 1 US$ 2.755 USD

Aquestive Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
200.11M 73.30M - 50.58M -7.87M -0.11 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aquestive Therapeutics News

Date Time Source News Article
6/07/202407:13Edgar (US Regulatory)Form 8-K - Current report
6/06/202415:05Edgar (US Regulatory)Form 8-K - Current report
6/03/202407:00GlobeNewswire Inc.Aquestive Therapeutics Announces Executive Appointments and..
5/28/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Present Anaphylmâ„¢ (epinephrine)..
5/13/202412:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/13/202412:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/09/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in The Citizens JMP..
5/07/202415:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/07/202415:21Edgar (US Regulatory)Form 8-K - Current report
5/07/202415:19GlobeNewswire Inc.Aquestive Therapeutics Reports First Quarter 2024 Financial..
4/29/202406:00GlobeNewswire Inc.Aquestive Therapeutics Receives U.S. FDA Approval and Market..
4/25/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Report First Quarter 2024..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AQST Message Board. Create One! See More Posts on AQST Message Board See More Message Board Posts

Historical AQST Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.953.102.722.901,300,008-0.20-6.78%
1 Month3.383.38982.723.051,084,544-0.63-18.64%
3 Months5.416.232.724.042,360,100-2.66-49.17%
6 Months2.126.231.843.861,839,3050.6329.72%
1 Year2.226.231.25143.541,085,2420.5323.87%
3 Years3.746.400.6182.99733,604-0.99-26.47%
5 Years4.0510.000.6183.99731,624-1.30-32.10%

Aquestive Therapeutics Description

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Your Recent History

Delayed Upgrade Clock